Irvine, CA - Rubicon Biotechnology LLC is pleased to announce a grant award from the US Army Medical Research & Development Command (USAMRDC) to study Rubicon’s Rapid Recovery technology in ocular cytoprotection. The project, titled “Rapid Delivery of Hsp72 for Ocular Cytoprotection After a Traumatic Brain Injury” is supported by the Assistant Secretary of Defense…
Read more
Rubicon Awarded Traumatic Brain Injury Grant from USAMRDC
Irvine, CA - Rubicon Biotechnology LLC is pleased to announce an award from the US Army Medical Research & Development Command (USAMRDC) to study Rubicon’s Rapid Recovery technology in traumatic brain injury (TBI). The 3-year study titled, "Intracellular Delivery of Hsp72 for Neural Cytoprotection After Traumatic Brain Injury”, includes the optimization and characterization of the…
Read more
Rubicon Announces National Eye Institute Grant
Lake Forest, CA - Rubicon Biotechnology, LLC is pleased to announce that it was awarded a SBIR Phase I grant by the National Eye Institute titled “Targeted Hsp72 as a Therapeutic for Central Retinal Artery Occlusion”. Rubicon is collaborating with Drs. Michael Gorin and Anna Matynia and their teams at the Stein Eye Institute at…
Read more
Rubicon Announces Publication in JACC
Lake Forest, CA - Rubicon Biotechnology, LLC announces the publication of preclinical results for our lead platform technology, Fv-Hsp72, for the treatment of stress injuries caused by a myocardial infarction. The article titled “Cardioprotective effects of HSP72 administration on ischemia-reperfusion injury", by collaborators from Rubicon and the laboratory of Jagat Narula, MD, PhD, Associate Dean for…
Read more
- 1
- 2